Difference between revisions of "Matt Fust"
| Line 15: | Line 15: | ||
Board member active in many companies in the Biotech field, including ArsenalBio, Altara Biotherapeutics, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceuticals. Senior Advisor for Out Leadership. From 2009 through 2013, he was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, culminating in the company’s sale to Amgen. He previously served as Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals (2003 – 2008), Chief Financial Officer of Perlegen Sciences (2002 – 2003), and Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 through the company’s acquisition by Johnson & Johnson in 2001. Also known as Matthew Fust. | Board member active in many companies in the Biotech field, including ArsenalBio, Altara Biotherapeutics, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceuticals. Senior Advisor for Out Leadership. From 2009 through 2013, he was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, culminating in the company’s sale to Amgen. He previously served as Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals (2003 – 2008), Chief Financial Officer of Perlegen Sciences (2002 – 2003), and Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 through the company’s acquisition by Johnson & Johnson in 2001. Also known as Matthew Fust. | ||
| + | |||
| + | ==See Also== | ||
| + | |||
| + | * [[LGBTQ Participants in Pharmaceutical, Vaccine and Biotech Studies]] | ||
==Further Reading/Research== | ==Further Reading/Research== | ||
Revision as of 20:43, 19 September 2021
Country
United States
Birth - Death
Occupation
Business
Description
Board member active in many companies in the Biotech field, including ArsenalBio, Altara Biotherapeutics, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceuticals. Senior Advisor for Out Leadership. From 2009 through 2013, he was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, culminating in the company’s sale to Amgen. He previously served as Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals (2003 – 2008), Chief Financial Officer of Perlegen Sciences (2002 – 2003), and Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 through the company’s acquisition by Johnson & Johnson in 2001. Also known as Matthew Fust.
